US bronchitis treatment market is projected to witness considerable growth during the forecast period. The rising prevalence of chronic respiratory diseases and increasing geriatric population are the major factors that augmenting the growth of bronchitis treatment market in US. The increasing demand for bronchitis treatment due to increasing and asthmatic patients in the US have endorsed the approval of cohesive reimbursement policies in the US, is further fueling the growth of the market. The US is the major market due to high healthcare expenditure and higher prevalence rate of respiratory diseases. The changing lifestyle is a major factor that increases the possibilities of diseases such as asthma and other respiratory diseases in North America such as inadequate diet and smoking. As per Centers for Disease Control and Prevention (CDC), in 2018, around 14 of every 100 US adults, aged 18 years or older, smoke cigarettes. This accounts for around 34.2 million adults in the US have a habit of smoking cigarettes. Therefore, around 16 million Americans are suffering from some smoking related diseases, including bronchitis. This, in turn, is driving the demand for effective treatment solutions for smoking related diseases, offering growth to the bronchitis treatment market in the US.
The bronchitis treatment market is classified on the basis of type of treatment, which includes drugs and oxygen therapy. The drugs segment is further segregated into antibiotics, anti-inflammatory drugs, bronchodilators, and others. Among these types of treatments, the drugs find its significant application in the bronchitis treatment across the globe. In addition, the bronchodilator is estimated to project a considerable CAGR during the forecast period. Bronchodilators are the first-line medication used to treatment of bronchitis, to clear the airway obstruction, which is considered as first-step in chronic bronchitis to ease breathing problems.
The US bronchitis treatment market is influenced by product development and advancements conducted by the market players. The key players of the bronchitis treatment market include Abbott Laboratories, Bayer AG, GlaxoSmithKline PLC, Novartis AG, Pfizer Inc., and Teva Pharmaceutical Industries Ltd. These players are playing a significant role in the growth of the bronchitis treatment market by providing various products and adopting several strategies such as merger and acquisition, partnerships and collaboration, technological development, and others.
RESEARCH METHODOLOGY
The market study of the US bronchitis treatment market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.
Secondary sources include:
The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions.
Market Segmentation:
The Report covers:
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. US Bronchitis Treatment Market by Type
5.1.1. Drugs
5.1.1.1. Antibiotics
5.1.1.2. Anti-inflammatory drugs
5.1.1.3. Bronchodilators
5.1.1.4. Others (Mucolytics)
5.1.2. Oxygen Therapy
6. Company Profiles
6.1. Abbott Laboratories
6.2. Aurobindo Pharma Ltd.
6.3. Bayer AG
6.4. Boehringer Ingelheim International GmbH
6.5. Cipla Ltd.
6.6. Dr Reddy's Laboratories Ltd.
6.7. GlaxoSmithKline PLC
6.8. Lupin Pharmaceuticals, Inc.
6.9. Merck & Co., Inc.
6.10. Novartis AG
6.11. Pfizer Inc.
6.12. Sanofi SA
6.13. Teva Pharmaceutical Industries Ltd.
1. US BRONCHITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
1. US BRONCHITIS TREATMENT MARKET SHARE BY TYPE, 2019 VS 2026 (%)
2. US BRONCHITIS TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)